Tumor Rebiopsy During Progression Under Immunotherapy for Patients With Lung Cancer
Recruiting
N/A
Interventional Study
Lung Cancer
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Interventional
- Purpose
- Diagnostic
- Participants needed
- 50 (estimated)
- Sponsor
- Assistance Publique - Hôpitaux de Paris · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The objective of the study aims to collect tumor tissue at the moment of progression under Immune checkpoint inhibitors (ICI) in biological resources center in Ambroise Paré hospital, in order to insure later study on molecular mechanism involving the progression of NSCLC and SCLC under ICI.
The further analysis of research will be performed in the EA 4340 unity, Biomarkers and Clinical Trials in…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Diagnosed NSCLC or SCLC;
* Patient treated priorly by ICI and progressed under ICI;
* Have provided written informed consent for the study;
* Be \>/= 18 years of age on day of signing informed consent.
Exclusion Criteria:
* Patient under guardianship or curatorship;
* Unable…
Contacts